Cargando…

Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis

BACKGROUND: Escitalopram is selective serotonin reuptake inhibitors (SSRIs) and one of the most commonly prescribed newer antidepressants (ADs) worldwide. We aimed to explore the efficacy, acceptability and tolerability of escitalopram in comparison with other ADs in the acute-phase treatment of maj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Juntao, Song, Xiaoyong, Wang, Chaoyang, Lin, Xuhong, Miao, Mingsan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675869/ https://www.ncbi.nlm.nih.gov/pubmed/38001423 http://dx.doi.org/10.1186/s12888-023-05382-8

Ejemplares similares

Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
por: Sun, Zuoli, et al.
Publicado: (2023)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Differential effects of antidepressants escitalopram versus lithium on Gs alpha membrane relocalization
por: Donati, Robert J, et al.
Publicado: (2015)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression
por: Bandu, Raju, et al.
Publicado: (2023)

3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders
por: Avram, Speranta, et al.
Publicado: (2010)

Effect of Escitalopram on White Blood Cells in Patients With Major Depression
por: Canan, Fatih, et al.
Publicado: (2009)

Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study
por: Woo, Young Sup, et al.
Publicado: (2017)

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece
por: Maniadakis, Nikos, et al.
Publicado: (2013)

Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability
por: Kirino, Eiji
Publicado: (2012)

Comparing the Effects of Bupropion and Escitalopram on Excessive Internet Game Play in Patients with Major Depressive Disorder
por: Nam, Beomwoo, et al.
Publicado: (2017)

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
por: Alkahtani, Manal E., et al.
Publicado: (2021)

Escitalopram-induced akathisia in a patient with major depressive disorder: A rare case report
por: Arshad, Hareem, et al.
Publicado: (2022)

Should antidepressants be used for major depressive disorder?
por: Jakobsen, Janus Christian, et al.
Publicado: (2020)

Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
por: Barba, Tommaso, et al.
Publicado: (2022)

Galanin(1-15) Potentiates the Antidepressant-like Effects Induced by Escitalopram in a Rat Model of Depression
por: García-Durán, Laura, et al.
Publicado: (2021)

Biodegradable polymer everolimus-eluting stents versus contemporary drug-eluting stents: a systematic review and meta‑analysis
por: Yin, Juntao, et al.
Publicado: (2023)

Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder
por: Kotzalidis, Georgios D., et al.
Publicado: (2021)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder
por: Martens, Marieke A. G., et al.
Publicado: (2021)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis
por: Kato, Masaki, et al.
Publicado: (2020)

Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder
por: Behr, Guilherme A., et al.
Publicado: (2012)

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

Mild cognitive disorder and depression: treatment with combination of galantamine and escitalopram
por: Zarra, Julio, et al.
Publicado: (2010)

Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression
por: Leonard, Brian, et al.
Publicado: (2010)

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
por: Singh, A B, et al.
Publicado: (2012)

Treatment of alcohol dependence in patients with co-morbid major depressive disorder – predictors for the outcomes with memantine and escitalopram medication
por: Muhonen, Leea H, et al.
Publicado: (2008)

Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: A pooled analysis of 4 Chinese clinical trials
por: Li, Guanjun, et al.
Publicado: (2017)

Sertraline versus escitalopram in South Asians with moderate to severe major depressive disorder: (SOUTH-DEP) a double-blind, parallel, randomized controlled trial
por: Raza, Sidra, et al.
Publicado: (2023)

Relapse and its modifiers in major depressive disorder after antidepressant discontinuation: meta-analysis and meta-regression
por: Kishi, Taro, et al.
Publicado: (2022)

CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression
por: Bernini de Brito, Rodrigo, et al.
Publicado: (2020)

ARPNet: Antidepressant Response Prediction Network for Major Depressive Disorder
por: Chang, Buru, et al.
Publicado: (2019)

Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants
por: Alkhafaji, Ali A, et al.
Publicado: (2012)

Efficacy of escitalopram for poststroke depression: a systematic review and meta-analysis
por: Feng, Rong-fang, et al.
Publicado: (2022)

Left DLPFC activity is associated with plasma kynurenine levels and can predict treatment response to escitalopram in major depressive disorder
por: Kamishikiryo, Toshiharu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2t9eqnmr4842b0sju3m6m133t3